LENZ Therapeutics (LENZ) Piper Sandler 36th Annual Healthcare Conference summary

Product overview and differentiation

• Developed a once-daily pharmaceutical eye drop that restores near vision for the full workday, targeting presbyopia in adults over 45.

• Uses aceclidine, a pupil-selective miotic, to improve near vision without negatively impacting distance vision, unlike pilocarpine-based products.

• Completed phase III trials, submitted NDA, and received a PDUFA date for August 8th next year, aiming for a U.S. launch in Q4.

Clinical data and patient experience

• 71% of patients achieved three lines of near vision improvement within 30 minutes; over 90% achieved two lines.

• Effect sustained for up to 10 hours, with 40% maintaining three lines and 69% maintaining two lines of improvement at that point.

• Mild ocular side effects and low headache incidence (7.6%), with headaches being transient and diminishing over time.

• 75% of study participants wanted to continue use, with most intending daily use; non-continuers were mainly older, less active individuals.

Market strategy and physician engagement

• Early and ongoing physician education campaigns emphasize the importance of pupil selectivity and product differentiation.

• ECP survey of 430 professionals showed 78% view the product as safe and tolerable, and over 80% are willing to sample and prescribe.

• Initial sales force of 100 reps targeting high-prescribing optometrists and ophthalmologists, with DTC marketing planned after physician education.